Experience MedTrace’s Evaluation Software, aQuant, at ASNC2024 in Austin, Texas

We’re excited to showcase our patented analysis software, aQuant, at the 29th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology, ASNC2024, from September 5-7 in Austin, Texas.

Visit MedTrace at booth no. 709, where you can:

  • Experience live demonstrations of MedTrace’s aQuant analysis software, currently in its final stages of development. Upon full regulatory approval, aQuant is expected to offer a comprehensive analysis of the quantitative myocardial blood flow during PET exams using 15O-water. 
     
    The latest version of aQuant showcased at ASNC2024 has all the clinical functionalities in place and will be used in MedTrace’s Phase III Clinical Trial for the blinded reads.       

 

  • Discuss the RAPID-WATER-FLOW trial sponsored by MedTrace with the company’s Clinical Affairs Team and get the latest updates on 15O-water research findings from around the globe.  
     
    MedTrace’s Phase III Clinical Trial seeks to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion PET imaging agent. Roughly one-fourth of patients have now been enrolled across eight hospitals in Europe and North America. Read more about the trial here. 

Stop by Booth no. 709 or Schedule a Meeting: 

We encourage all ASNC2024 participants interested in learning more about MedTrace’s patented software and Phase III Clinical Trial to reach out in advance and schedule a meeting or simply stop by booth no. 709.

Contact:

René Duvander
Director, Market Development
[email protected]

MedTrace’s technologies are not cleared to market and available for investigational research only. 

About MedTrace

MedTrace is a pharma and medical device company with a 15O-water point-of-care solution under development. The solution consists of patented hardware for on-demand manufacturing, dosing, and infusion of 15O-water and patented software to analyze PET images. The company has an ongoing Phase III Clinical Trial, RAPID-WATER-FLOW, that seeks to evaluate the diagnostic accuracy and safety of  15O-water as a myocardial perfusion PET imaging agent.